Tyra Biosciences, Inc. (TYRA) NASDAQ

12.97

+0.43(+3.43%)

Updated at September 26 04:00PM

Currency In USD

Tyra Biosciences, Inc.

Address

2656 State Street

Carlsbad, CA 92008

United States of America

Phone

619 728 4760

Sector

Healthcare

Industry

Biotechnology

Employees

60

First IPO Date

September 15, 2021

Key Executives

NameTitlePayYear Born
Dr. Todd Harris Ph.D.Co-Founder, President, Chief Executive Officer, Secretary, Treasurer & Director1.07M1979
Dr. Ronald V. Swanson Ph.D.Chief Scientific Officer536,1881963
Dr. Douglas Warner M.D.Chief Medical Officer627,9001972
Mr. Ali D. Fawaz J.D.General Counsel629,230N/A
Mr. Daniel BensenCo-Founder & Chief Operating Officer737,6431975
Ms. Sarah HonigSenior Vice President of Corporate Development & Strategy0N/A
Dr. Piyush R. Patel Ph.D.Chief Development Officer01965
Dr. Robert L. Hudkins Ph.D.Chief Technology Officer01955
Mr. Erik GoluboffSenior Vice President of Clinical Development0N/A
Liz PaganoSenior Vice President of Human Resources0N/A

Description

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.